Condition (MeSH)
Muir-Torre Syndrome
ClinicalTrials.gov lists 2 trials for Muir-Torre Syndrome or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 1.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
2 of the 2 trials are tagged with Muir-Torre Syndrome itself; the rest are tagged with a narrower condition beneath it.
When did Muir-Torre Syndrome trials start? (2)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2017 | 1 |
No forecast is made for this condition: it averages 0.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Muir-Torre Syndrome trials in? (2)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 2 | 1 |
| Not applicable | 1 |
How many Muir-Torre Syndrome trials are recruiting? (2)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 1 |
| Active, not recruiting | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Muir-Torre Syndrome trials? (1)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Cancer Institute (NCI) | 1 |
Which publications cover Muir-Torre Syndrome? (4)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Characterization of sebaceous and non-sebaceous cutaneous manifestations in patients with lynch syndrome: a systematic review. | Familial cancer | 2023 | Yes |
| Cumulative risk of skin tumours in patients with Lynch syndrome. | The British journal of dermatology | 2018 | Yes |
| Sebaceous adenomas of the eyelid and Muir-Torre Syndrome. | The British journal of ophthalmology | 2015 | Yes |
| Sebaceous carcinoma of the eyelid and Muir-Torre syndrome. | JAMA ophthalmology | 2014 | Yes |
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Muir-Torre syndrome | 587 | Exact | Orphanet Rare Disease Ontology (ORDO) |
| Muir-Torre syndrome | 587 | Exact | Orphadata Science knowledge files, Product 1 |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials, prevalence, and sub-conditions in mesh.
Not computed for conditions with fewer than 10 trials: drugs tested.